Zobrazeno 1 - 10
of 3 364
pro vyhledávání: '"Brakenhoff"'
Autor:
Tara Muijlwijk, Irene H. Nauta, Anabel van der Lee, Kari J. T. Grünewald, Arjen Brink, Sonja H. Ganzevles, Robert J. Baatenburg de Jong, Lilit Atanesyan, Suvi Savola, Mark A. van de Wiel, Laura A. N. Peferoen, Elisabeth Bloemena, Rieneke van de Ven, C. René Leemans, Jos B. Poell, Ruud H. Brakenhoff
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key characteristics of cancer development. Nonetheless, some tumors show hardly any CNAs, a remarka
Externí odkaz:
https://doaj.org/article/225436245a4a4f2badda609a77918405
Autor:
Sylvia M. Brakenhoff, Thymen Theijse, Peter van Wijngaarden, Christian Trautwein, Jonathan F. Brozat, Frank Tacke, Pieter Honkoop, Thomas Vanwolleghem, Dirk Posthouwer, Stefan Zeuzem, Ulrike Mihm, Heiner Wedemeyer, Thomas Berg, Solko W. Schalm, Robert J. de Knegt
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background and Aims Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelect
Externí odkaz:
https://doaj.org/article/c576f08441324371baa5a462203e8cd0
Autor:
Anne M. van Harten, Ronak Shah, D. Vicky de Boer, Marijke Buijze, Maaike Kreft, Ji-Ying Song, Lisa M. Zürcher, Heinz Jacobs, Ruud H. Brakenhoff
Publikováno v:
Oncogenesis, Vol 13, Iss 1, Pp 1-10 (2024)
Abstract Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities
Externí odkaz:
https://doaj.org/article/a37c66cfac3e4d369e5284cf90649cbc
Autor:
Sylvia M. Brakenhoff, Heng Chi, Pieter Friederich, Michail Doukas, Caroline den Hoed, Hajo J. Flink, Robert J. de Knegt, Robert A. de Man
Publikováno v:
Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 252-259 (2024)
Introduction: Emerging evidence suggests that long-term nucleos(t)ide analogue (NA) therapy can be ceased in a selective group of chronic hepatitis B (CHB). This is being gradually implemented in clinical practice. Case Presentation: A 68-year-old ma
Externí odkaz:
https://doaj.org/article/b5104e93061d4d369b3810d06033a46f
Autor:
Andjela Markovic, Vladimir Kovacevic, Timo B Brakenhoff, Duco Veen, Paul Klaver, Marianna Mitratza, George S Downward, Diederick E Grobbee, Maureen Cronin, Brianna M Goodale
Publikováno v:
Journal of Medical Internet Research, Vol 26, p e51120 (2024)
BackgroundRapid development and implementation of vaccines constituted a crucial step in containing the COVID-19 pandemic. A comprehensive understanding of physiological responses to these vaccines is important to build trust in medicine. ObjectiveT
Externí odkaz:
https://doaj.org/article/ac879f0a1eaa4048aaa9c4142c3dac0b
Autor:
Bernard A Fox, Rieneke van de Ven, Carmen Ballesteros-Merino, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans, Laura A N Peferoen, Elisabeth Bloemena, Fatima Ekhlas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20% of patients respond.
Externí odkaz:
https://doaj.org/article/706241e19a784c6ebfc691493690aafb
Autor:
Tanja D de Gruijl, Rieneke van de Ven, K Hakki Karagozoglu, Pim de Graaf, Ronald Boellaard, Ruud H Brakenhoff, C René Leemans, Gerben J C Zwezerijnen, C Willemien Menke-van der Houven van Oordt, Iris H C Miedema, Niels E Wondergem, Jan-Jaap Hendrickx, Simone E J Eerenstein, Rolf J Bun, Dorien C Mulder, Jens Voortman, Albert D Windhorst, J Pascal Hagers, Laura A N Peferoen, Elisabeth Bloemena
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome.Methods In this study, 16 evaluable patients with stage III/IV oral cancer were treated
Externí odkaz:
https://doaj.org/article/3a0f349d6bd74bb79ff5d9ffc2077cbb
Autor:
von Buchwald, Christian, Jakobsen, Kathrine Kronberg, Carlander, Amanda-Louise Fenger, Tous, Sara, Grønhøj, Christian, Rasmussen, Jacob H., Brooks, Jill, Taberna, Miren, Mena, Marisa, Morey, Francisca, Bruni, Laia, Batis, Nikolaos, Brakenhoff, Ruud H., René Leemans, C., Jong, Robert J.Baatenburg de, Klussmann, Jens Peter, Wuerdemann, Nora, Wagner, Steffen, Dalianis, Tina, Marklund, Linda o, Mirghani, Haïtham, Schache, Andrew, James, Jaqueline A., Huang, Shao Hui, O’Sullivan, Brian, Nankivell, Paul, Broglie, Martina A., Hoffmann, Markus, Quabius, Elgar Susanne, Anderson, Lesley A., Craig, Stephanie G., Alemany, Laia, Mehanna, Hisham
Publikováno v:
In European Journal of Cancer November 2024 211
Autor:
Natasha Slesnick, Brittany Brakenhoff, Laura J. Chavez, Caleb L. Cuthbertson, Ruri Famelia, Xin Feng, Jodi Ford, Eugene Holowacz, Soren Jaderlund, Kelly Kelleher, Ellison Luthy, Allen M. Mallory, Alexis Pizzulo, Tatiana D. Slesnick, Tansel Yilmazer
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Background While research on substance using youth experiencing homelessness (YEH) is increasing, there is a dearth of information regarding effective prevention interventions for these youth. Suicide is the leading cause of death among YEH
Externí odkaz:
https://doaj.org/article/cc671e3d1f6349c1a7cc900ea96e4e36
Autor:
Reinout H. de Roest, Marijke Stigter van Walsum, Karlijn van der Schilden, Ruud H. Brakenhoff
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Background Cisplatin- based chemoradiotherapy is a crucial pillar in the treatment of HNSCC. The use of cisplatin comes with high toxicity rates as 35% of patients cannot sustain the planned dose while response is unpredictable. Unfortunatel
Externí odkaz:
https://doaj.org/article/04e29c3b117b4e958a84768595cae5cd